A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Completed · Phase 3

Conditions studied: Lymphoma, Follicular

In brief

This is a Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the statistical equivalence of efficacy, safety and immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in asymptomatic patients with Low Tumor Burden Follicular Lymphoma.

Key facts

Study ID: NCT02809053
Run by: Archigen Biotech Limited
People needed: 315
Starts: 2017-01-18
Expected to finish: 2020-01-10
Last updated by the study team: 2020-10-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with histologically-confirmed Low Tumor Burden Follicular Lymphoma, without B symptoms, Ann Arbor stage II to Non-Hodgkin's Lymphoma (NHL) (CD20+ Follicular Lymphoma of Grades 1, 2, or 3a)
Low tumor burden according to The Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria defined as:
Normal serum lactate dehydrogenase (LDH)
No mass ≥7 cm.
Less than 3 nodal sites, each with diameter >3 cm
No systemic or B symptoms (fever >38°C for 3 consecutive days; recurrent, drenching night sweats; unintentional weight loss exceeding 10% body weight in the last 6 months.
No splenomegaly ≥16 cm by CT scan.
No risk of vital organ compression.
No pleural or peritoneal serous effusion.
No leukemic phase >5,000/µL circulating tumor cells.
No cytopenias (defined as platelets <100,000/mm3, hemoglobin <10 g/dL, or absolute neutrophil count <1,500/mm3).
Patients not previously treated for their FL, including any previous treatment for FL under clinical trials except localized radiation therapy for previous limited stage disease.

You may not qualify if…

Previous treatment with any chemotherapy and/or rituximab or other monoclonal antibody.
Prior radiotherapy completed <28 days before study enrollment.
Anticipated need for concomitant administration of any other experimental drug, or a concomitant chemotherapy, anticancer hormonal therapy, radiotherapy, or immunotherapy during study participation.
Concomitant disease which requires continuous therapy with corticosteroids at doses equivalent to prednisolone >20 mg/day.
Transformation to high-grade lymphoma secondary to previously untreated low-grade lymphoma.
Prior or concomitant malignancies within 5 years prior to screening, with the exceptions of non-melanoma skin cancer, adequately treated carcinoma in situ of the cervix, adequately treated breast cancer in situ, and localized prostate cancer stage T1c, provided that the patient underwent curative treatment and remains relapse free.
Patients with a body surface area >3.0 m2.
Major surgery (excluding lymph node biopsy) within 28 days prior to randomization.
Primary or secondary immunodeficiency (history of, or currently active), including known history of human immunodeficiency virus (HIV) infection or positive test at screening.
Acute, severe infection (e.g., sepsis and opportunistic infections), or active, chronic or persistent infection that might worsen with immunosuppressive treatment (e.g., herpes zoster).
Positive serological test for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C serology.
Confirmed current active tuberculosis (TB)
Central nervous system (CNS) or meningeal involvement, or cord compression by the lymphoma; history of CNS lymphoma
History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug (e.g., hypersensitivity or allergy to murine products).
Patients who have significant cardiac disease, including but not limited to history of congestive heart failure (New York Heart Association Class III/IV; see Appendix 7), unstable angina, or uncontrolled cardiac arrhythmia.
Uncontrolled or severe hypertension, or cerebrovascular disease.
Serious underlying medical conditions that, per the Investigator's discretion, could impair the ability of the patient to participate in the trial
Any other co-existing medical or psychological condition(s) that will preclude participation in the study or compromise ability to give informed consent and/or comply with study procedures.
Treatment with any investigational medicinal product (IMP) within 4 weeks prior to initiation of 1st infusion of study drug, or treatment with a drug that has not received regulatory approval for any indication within 4 weeks or a minimum of 5 half-lives, whichever is longer, of the 1st infusion of study drug.
Receipt of a live/attenuated vaccine within 6 weeks prior to the screening visit.
Females who are pregnant, breastfeeding, or planning a pregnancy during the treatment period or within 12 months after the last infusion of study drug.
Patients who are investigational site staff members directly involved in the conduct of the trial, and their family members, site staff members otherwise supervised by the investigator, or patients who are Archigen employees directly involved in the conduct of the trial.

Where it is running

Research site — Whittier, California, United States
Research Site — Canberra, Australian Capital Territory, Australia
Research site — Temuco, Araucania, Chile
Research site — Hradec Králové, Czechia
Research site — Prague, Czechia
Reasearch site — Prague, Czechia
Research site — Libourne, Gironde, France
Research site — Poitiers, Vienne, France
Research site — Hamburg, Germany
Research site — Budapest, Hungary
Research site — San Giovanni Rotondo, Foggia, Italy
Research site — Terni, Italy
Research site — Mexico City, Mexico City, Mexico
Research site — Pretoria, Gauteng, South Africa
Research site — Busan, South Korea
Research site — Seoul, South Korea
Research site — Seoul, South Korea
Research site — L'Hospitalet de Llobregat, Barcelona, Spain
Research site — Cadiz, Spain
Research site — Madrid, Spain
Research site — Ankara, Turkey (Türkiye)
Research site — Istanbul, Turkey (Türkiye)
Research site — Mersin, Turkey (Türkiye)
Research site — Samsun, Turkey (Türkiye)
Research site — Norwich, Norfolk, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.